Literature DB >> 29746316

The clinical significance of KIT mutations in melanoma: a meta-analysis.

Hui Z Gong, He Y Zheng, Jun Li.   

Abstract

This study aimed to evaluate the association of KIT mutations with clinicopathologic features of melanomas using a meta-analysis and to identify differences between Asian and White populations using subgroup analyses. We selected 32 studies from the literature including 5224 patients. The pooled data were combined, and odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Heterogeneity and publication bias were also determined. KIT mutations were reported in 497 (9.5%) of 5224 patients with melanomas, and were associated significantly with age, clinical melanoma subtype, anatomic location, and chronic sun-damage (CSD), but not with sex, histological type, Breslow thickness, ulceration, mitotic rate, or tumor stage. The incidence of KIT mutation was significantly higher in older individuals (OR=1.296, 95% CI: 1.025-1.641; P=0.031), and showed a positive association with mucosal melanoma (OR=1.363, 95% CI: 1.094-1.697; P=0.006), acral melanoma (OR=1.374, 95% CI: 1.123-1.682; P=0.02), and CSD (OR=1.880, 95% CI: 1.127-3.136; P=0.016), but a negative relationship with melanomas arising in non-CSD skin (OR=0.562, 95% CI: 0.392-0.805; P=0.002). The frequency of KIT mutations was associated negatively with melanomas located on the extremities. KIT mutations, which are critical in the genetic pathogenesis of melanomas, define a unique subtype of melanoma associated closely with older age, and acral, mucosal, or CSD sites, but not associated with any histological features or tumor stage. Although the KIT mutation rate is higher in White than Asian populations, no significant difference in clinical association with KIT mutations was detected between the two groups.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29746316     DOI: 10.1097/CMR.0000000000000454

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  10 in total

Review 1.  Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies.

Authors:  Anastasia Gkiala; Sotiria Palioura
Journal:  Clin Ophthalmol       Date:  2020-10-09

Review 2.  KIT and Melanoma: Biological Insights and Clinical Implications.

Authors:  Duc Daniel M Pham; Samantha Guhan; Hensin Tsao
Journal:  Yonsei Med J       Date:  2020-07       Impact factor: 2.759

3.  KIT Mutation Incidence and Pattern of Melanoma in Central Europe.

Authors:  V Doma; T Barbai; M-A Beleaua; I Kovalszky; E Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2019-12-17       Impact factor: 3.201

Review 4.  Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.

Authors:  Ernesto Rossi; Giovanni Schinzari; Brigida Anna Maiorano; Monica Maria Pagliara; Alessandro Di Stefani; Emilio Bria; Ketty Peris; Maria Antonietta Blasi; Giampaolo Tortora
Journal:  Int J Mol Sci       Date:  2019-10-31       Impact factor: 5.923

5.  FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.

Authors:  Pauline Tétu; Julie Delyon; Jocelyne André; Coralie Reger de Moura; Malak Sabbah; Ghanem E Ghanem; Maxime Battistella; Samia Mourah; Céleste Lebbé; Nicolas Dumaz
Journal:  Cancers (Basel)       Date:  2020-04-25       Impact factor: 6.639

Review 6.  Molecular targets for anticancer therapies in companion animals and humans: what can we learn from each other?

Authors:  Irati Beltrán Hernández; Jannes Z Kromhout; Erik Teske; Wim E Hennink; Sebastiaan A van Nimwegen; Sabrina Oliveira
Journal:  Theranostics       Date:  2021-02-06       Impact factor: 11.556

7.  BRAF, C-KIT, and NRAS mutations correlated with different clinicopathological features: an analysis of 691 melanoma patients from a single center.

Authors:  Min Ren; Jing Zhang; Yunyi Kong; Qianming Bai; Peng Qi; Ling Zhang; Qian Wang; Xiaoyan Zhou; Yong Chen; Xiaoli Zhu
Journal:  Ann Transl Med       Date:  2022-01

Review 8.  Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies.

Authors:  Taylor Rager; Adam Eckburg; Meet Patel; Rong Qiu; Shahina Gantiwala; Katrina Dovalovsky; Kelly Fan; Katie Lam; Claire Roesler; Aayush Rastogi; Shruti Gautam; Namrata Dube; Bridget Morgan; S M Nasifuzzaman; Dhruv Ramaswami; Varun Gnanasekar; Jeffrey Smith; Aftab Merchant; Neelu Puri
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

Review 9.  Novel Biomarkers and Therapeutic Targets for Melanoma.

Authors:  Noa Sabag; Alexander Yakobson; Meir Retchkiman; Eldad Silberstein
Journal:  Int J Mol Sci       Date:  2022-10-01       Impact factor: 6.208

10.  The Human Melanoma Proteome Atlas-Complementing the melanoma transcriptome.

Authors:  Lazaro Hiram Betancourt; Jeovanis Gil; Aniel Sanchez; Viktória Doma; Magdalena Kuras; Jimmy Rodriguez Murillo; Erika Velasquez; Uğur Çakır; Yonghyo Kim; Yutaka Sugihara; Indira Pla Parada; Beáta Szeitz; Roger Appelqvist; Elisabet Wieslander; Charlotte Welinder; Natália Pinto de Almeida; Nicole Woldmar; Matilda Marko-Varga; Jonatan Eriksson; Krzysztof Pawłowski; Bo Baldetorp; Christian Ingvar; Håkan Olsson; Lotta Lundgren; Henrik Lindberg; Henriett Oskolas; Boram Lee; Ethan Berge; Marie Sjögren; Carina Eriksson; Dasol Kim; Ho Jeong Kwon; Beatrice Knudsen; Melinda Rezeli; Johan Malm; Runyu Hong; Peter Horvath; A Marcell Szász; József Tímár; Sarolta Kárpáti; Peter Horvatovich; Tasso Miliotis; Toshihide Nishimura; Harubumi Kato; Erik Steinfelder; Madalina Oppermann; Ken Miller; Francesco Florindi; Quimin Zhou; Gilberto B Domont; Luciana Pizzatti; Fábio C S Nogueira; Leticia Szadai; István Balázs Németh; Henrik Ekedahl; David Fenyö; György Marko-Varga
Journal:  Clin Transl Med       Date:  2021-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.